Home Visit app to optimize virtual clinical trials

07 May 2020

Cmed Technology announced today the encapsia Home Visit app is now available to capture and manage clinical trial data from patients at home or in the community. The app works seamlessly with all the other encapsia apps, including web EDC (Entry app) and direct data capture (esource app) to provide tremendous flexibility in the choice of data capture methods both before and during a study. This helps maintain patient participation and clinical data flow which is particularly compelling to minimize disruption during the COVID-19 pandemic as well as in the new landscape for clinical trials that is expected to follow.

Support for Virtual Clinical Trials from Cmed

30 Apr 2020

The dramatic coronavirus (COVID-19) pandemic has disrupted all aspects of daily life including clinical trials. Medical staff limitations and reorganizations, travel bans and access restrictions to medical facilities have challenged sponsors and sites’ current clinical trial processes.
The coronavirus outbreak has effectively forced a change in patient care and clinical trials. To continue bringing new therapies to market and support patients, sites and sponsors have accelerated the adoption of new technologies into decentralized trials or hybrid trials.

A message for our clients, investigator sites and industry partners

06 Apr 2020

The global COVID-19 crisis has fundamentally impacted the way we live our lives as well as the operation of the entire drug development community. During the early stages of the pandemic the Cmed leadership team has implemented a number of measures to ensure the safety of our employees, clients and partners, as well as ensuring the continued delivery of our CRO services and our encapsia clinical data system. Our goal has been to minimise the impact of COVID-19 on our business, our clients, investigator sites and patients.

Cmed’s response to the Coronavirus (COVID-19) pandemic

Written by David M Connelly, Chief Executive Officer

Thank you for your continued loyalty and trust in Cmed during these uncertain times. We are continuously monitoring the evolving circumstances surrounding the COVID-19 outbreak and continue operating as normal.

Our highest priority is to maintain the health and safety of our people, customers, partners and suppliers while meeting our service commitments. Cmed has implemented a range of measures in line with World Health Organization guidance to minimise the risks for employees and customers.

Business Continuity procedures have been in place since 10th March 2020 and the Cmed Management Committee meets on a daily basis to monitor the situation. We are actively engaged in managing the implementation of these procedures which include all our staff working remotely across all geographic locations, the deployment of a digital-first strategy and the monitoring of official regulatory guidance.

We continue to update our team members globally with news and information. We also encourage all our employees to be mindful of their health, of others and to support each other.

Despite the recent issues in many countries, we are still able to provide services and technology solutions for all our customers as normal. During these difficult times, encapsia – the game changing EDC and eSource platform – continues to operate with 100% uptime. We are proud to offer industry leading software and features to give our customers the utmost flexibility to allow their studies to continue through all eventualities.

With 20 years of experience as a smart technology-led CRO, Cmed has a strong track record of keeping deliveries on time, to quality and on budget. We believe we are all in this together and will continue to follow our Guiding Principle: We are one team.